Why did GNCA stock fall to USD 0.0001 pre-market?

The drop reflects Chapter 11 restructuring, near-zero market capitalization, thin liquidity, and limited trading interest. These factors together compress bid levels and amplify price moves in the United States market.

What is Meyka AI's grade for GNCA and what does it mean?

Meyka AI rates GNCA **62.58/100** (Grade B, Suggestion: HOLD). The grade considers S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. It is informational, not investment advice.

What is the 12-month forecast for GNCA stock?

Meyka AI's model projects **USD 0.0010** in 12 months versus the current **USD 0.0001**, implying **900.00%** upside in a base-case scenario. Forecasts are projections and not guarantees.

Is GNCA at risk of NASDAQ delisting?

Yes. Ongoing Chapter 11 outcomes and extremely low share price raise delisting risk. Investors should monitor SEC filings and exchange notices for formal delisting information.

US Stocks

GNCA stock at $0.0001 pre-market on NASDAQ: Chapter 11 legacy keeps pressure

ByHuzaifa Zahoor March 6, 2026March 6, 2026

GNCA stock opened pre-market at USD 0.0001, down 97.44% from the previous close, making it one of the top pre-market losers on NASDAQ in the United States. Traders saw volume of 30,268 shares as the company’s Chapter 11 reorganization and near-zero market cap weighed on liquidity. This article examines why Genocea Biosciences, Inc. (GNCA) fell sharply, connects recent corporate events to price action, reviews key metrics, and sets out our Meyka AI model forecast and risk signals for investors.